MapLight Therapeutics, Inc.
MapLight Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on October 28, 2026, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 17.9 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| October 28, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| November 15, 2027 | ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD) | Trial Milestone | Phase 2 |
| December 15, 2027 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Trial Milestone | Phase 2 |
| March 15, 2029 | An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis | Trial Milestone | Phase 2 |
| February 15, 2030 | A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia | Trial Milestone | Phase 2 |
Track MPLT alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MPLT in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| August 13, 2026 | Quarterly results filed (8-K) | Earnings | — |
| July 27, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| June 22, 2026 | 8-K filed: Reg FD disclosure, Other event | Filing | — |
| June 18, 2026 | 8-K filed: Leadership change | Corporate | — |
| June 4, 2026 | A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia | Trial Milestone | Phase 2 |
| May 14, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 29, 2026 | 8-K filed: Leadership change | Corporate | — |
| March 26, 2026 | Quarterly results filed (8-K) | Earnings | — |
| March 10, 2026 | ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD) | Trial Milestone | Phase 2 |
| January 9, 2026 | Quarterly results filed (8-K) | Earnings | — |
| December 4, 2025 | Quarterly results filed (8-K) | Earnings | — |
| October 29, 2025 | 8-K filed: Other event | Filing | — |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.